Adverse Effects of Anticholinergic Drugs on Cognition and Mobility: Cutoff for Impairment in a Cross-Sectional Study in Young–Old and Old–Old Adults

  • Elpidio Attoh-Mensah
  • Gilles Loggia
  • Pascale Schumann-Bard
  • Rémy Morello
  • Pablo Descatoire
  • Christian Marcelli
  • Chantal ChavoixEmail author
Original Research Article



Drugs with anticholinergic properties are commonly prescribed in older adults despite growing evidence of their adverse outcomes. Several issues regarding these detrimental effects remain unresolved, such as the putative existence of a threshold above which anticholinergic drug consumption impairs cognitive or mobility performance.


We aimed to investigate the number of anticholinergic drugs and the anticholinergic burden that leads to mobility or cognitive impairment and compare the effects in community-dwelling older adults in two age groups (“young–old” 55–74 vs. “old–old” ≥ 75 years).


In a cross-sectional study, we identified drugs with anticholinergic (antimuscarinic) properties using the Anticholinergic Drug Scale. Cognition was assessed using the Mini Mental State Examination (MMSE) and the Trail Making Test (TMT-A and TMT-B), and mobility was assessed using the Timed Up and Go (TUG) test.


The study population consisted of 177 volunteers, 114 of whom were classed as young–old and 63 were classed as old–old adults. Despite the lack of cutoff values for impaired outcomes in young-old adults, impaired MMSE were significantly more numerous in users than in nonusers of anticholinergic drugs. In old–old adults, receiver operating characteristic (ROC) curve analysis indicated that taking a single anticholinergic drug per day was associated with impaired TMT-B completion time, TMT difference score (B–A), and TUG scores. The cutoff for anticholinergic burden was also one for these same outcomes. Based on these cutoff values, multivariate logistic regressions in old–old adults showed that the increased risk of impaired cognition and mobility was independent of confounding factors, including comorbidities. They also suggested that anticholinergic drugs would affect mobility through executive functions.


Drugs with anticholinergic (antimuscarinic) properties are associated with cognitive impairment in individuals as young as 55 years, and only one such drug per day, regardless of its anticholinergic burden, is associated with both impaired cognition and impaired mobility in old–old adults. Therefore, wherever possible, clinicians should avoid prescribing drugs with anticholinergic properties.



The authors thank Drs. Valérie Caridroit, Thiphaine Ciappucini, Murielle Michel, and Pascale Lescure for their participation in the medical examinations, Kristell Pothier for her significant contribution to the experimental part, Anita Jamet for her contribution to the recruitment of participants, and Valérie Constans for English proofreading.

Compliance with Ethical Standards


This work was supported by the French Ministry of Health (PHRC Programme Hospitalier de Recherche Clinique 2011 no. 2011-A00534-37), and E. Attoh-Mensah was supported by the Togolese Ministry of Higher Education and Research (No. 525/MESR/SG/DBS) and the Normandy Association for Physiology Research (ANDREP).

Conflict of interest

EA-M, GL, PS-B, RM, PD, CM, and CC have no conflicts of interest that are directly relevant to the content of this article.

Ethical approval

The Lower Normandy Ethics Committee approved this study (no. 2011-A00534-37; clinical trial registration number: NCT02292316).

Informed consent

Each participant signed and provided written informed consent.

Supplementary material

40266_2019_743_MOESM1_ESM.pdf (52 kb)
Supplementary material 1 (PDF 52 kb)


  1. 1.
    Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging. 2009;4:225–33.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Dauphinot V, Mouchoux C, Veillard S, Delphin-Combe F, Krolak-Salmon P. Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders. Alzheimers Res Ther. 2017;9(1):58.CrossRefGoogle Scholar
  3. 3.
    Cancelli I, Gigli GL, Piani A, et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J Clin Psychopharmacol. 2008;28(6):654–9.CrossRefGoogle Scholar
  4. 4.
    Ferret L, Ficheur G, Delaviez E, et al. Inappropriate anticholinergic drugs prescriptions in older patients: analysing a hospital database. Int J Clin Pharm. 2018;40(1):94–100.CrossRefGoogle Scholar
  5. 5.
    de Germay S, Lapeyre-Mestre M, Montastruc J-L, Montastruc F. Atropinic burden and anticholinergic drugs: interest and application in clinical practice in the elderly. Therapie. 2018.Google Scholar
  6. 6.
    Andre L, Gallini A, Montastruc F, et al. Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the Multidomain Alzheimer Preventive Trial (MAPT) study. Br J Clin Pharmacol. 2018.Google Scholar
  7. 7.
    Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6.CrossRefGoogle Scholar
  8. 8.
    Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.CrossRefGoogle Scholar
  9. 9.
    Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10(5):751–65.CrossRefGoogle Scholar
  10. 10.
    Mueller C, Rajkumar AP, Wan YM, et al. Assessment and management of neuropsychiatric symptoms in Parkinson’s disease. CNS Drugs. 2018;32(7):621–35.CrossRefGoogle Scholar
  11. 11.
    Francis J. Drug-induced delirium. CNS Drugs. 1996;5(2):103–14.CrossRefGoogle Scholar
  12. 12.
    Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25–35.CrossRefGoogle Scholar
  13. 13.
    Lechevallier-Michel N, Molimard M, Dartigues J-F, Fabrigoule C, Fourrier-Réglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 2005;59(2):143–51.CrossRefGoogle Scholar
  14. 14.
    Grande G, Tramacere I, Vetrano DL, et al. Role of anticholinergic burden in primary care patients with first cognitive complaints. Eur J Neurol. 2017;24(7):950–5.CrossRefGoogle Scholar
  15. 15.
    Ziad A, Olekhnovitch R, Ruiz F, et al. Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort. J Neurol Neurosurg Psychiatry. 2018;89(10):1107–15.CrossRefGoogle Scholar
  16. 16.
    Chuang Y-F, Elango P, Gonzalez CE, Thambisetty M. Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults. Alzheimers Dement (N Y). 2017;3(3):471–9.Google Scholar
  17. 17.
    Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209–20.CrossRefGoogle Scholar
  18. 18.
    Cao Y-J, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther. 2008;83(3):422–9.CrossRefGoogle Scholar
  19. 19.
    Gnjidic D, Bell JS, Hilmer SN, Lönnroos E, Sulkava R, Hartikainen S. Drug Burden Index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44(5):458–67.CrossRefGoogle Scholar
  20. 20.
    Zia A, Kamaruzzaman S, Myint PK, Tan MP. Anticholinergic burden is associated with recurrent and injurious falls in older individuals. Maturitas. 2016;84:32–7.CrossRefGoogle Scholar
  21. 21.
    Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med. 2009;122(12):1142–1149.e1–2.CrossRefGoogle Scholar
  22. 22.
    Langeard A, Pothier K, Morello R, et al. Polypharmacy cut-off for gait and cognitive impairments. Front Pharmacol. 2016;7:296.CrossRefGoogle Scholar
  23. 23.
    Tariot PN, Patel SV, Cox C, Henderson RE. Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology (Berl). 1996;125(1):50–6.CrossRefGoogle Scholar
  24. 24.
    Pothier K, Benguigui N, Kulpa R, Chavoix C. Multiple object tracking while walking: similarities and differences between young, young–old, and old–old adults. J Gerontol B Psychol Sci Soc Sci. 2015;70(6):840–9.CrossRefGoogle Scholar
  25. 25.
    Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012;60(11):2127–36.CrossRefGoogle Scholar
  26. 26.
    Muir SW, Gopaul K, Montero Odasso MM. The role of cognitive impairment in fall risk among older adults: a systematic review and meta-analysis. Age Ageing. 2012;41(3):299–308.CrossRefGoogle Scholar
  27. 27.
    Levasseur R, Sabatier J-P, Guilcher C, et al. Medical management of patients over 50 years admitted to orthopedic surgery for low-energy fracture. Joint Bone Spine. 2007;74(2):160–5.CrossRefGoogle Scholar
  28. 28.
    Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27(7):387–404.CrossRefGoogle Scholar
  29. 29.
    de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003;56(3):221–229.Google Scholar
  30. 30.
    Rosas-Carrasco O, González-Flores E, Brito-Carrera AM, et al. Assessment of comorbidity in elderly. Rev Med Inst Mex Seguro Soc. 2011;49(2):153–62.PubMedGoogle Scholar
  31. 31.
    Harboun M, Ankri J. Comorbidity indexes: review of the literature and application to studies of elderly population. Rev Epidemiol Sante Publique. 2001;49(3):287–98.PubMedGoogle Scholar
  32. 32.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.Google Scholar
  33. 33.
    Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–6.CrossRefGoogle Scholar
  34. 34.
    Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, et al. Construct validity of the trail making test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc. 2009;15(3):438–50.CrossRefGoogle Scholar
  35. 35.
    Senior G, Piovesana A, Beaumont P. Discrepancy analysis and Australian norms for the Trail Making Test. Clin Neuropsychol. 2018;32(3):510–23.CrossRefGoogle Scholar
  36. 36.
    Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.CrossRefGoogle Scholar
  37. 37.
    Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.CrossRefGoogle Scholar
  38. 38.
    Kalafat M, Hugonot-Diener L, Poitrenaud J. The Mini Mental State (MMS): French standardization and normative data [Standardisation et étalonnage français du “Mini Mental State” (MMS) version GRÉCO]. Revue de Neuropsychologie. 2003;13:209–36.Google Scholar
  39. 39.
    Bohannon RW. Reference values for the timed up and go test: a descriptive meta-analysis. J Geriatr Phys Ther. 2006;29(2):64–8.CrossRefGoogle Scholar
  40. 40.
    Delacour H, Servonnet A, Perrot A, Vigezzi JF, Ramirez JM. ROC (receiver operating characteristics) curve: principles and application in biology. Ann Biol Clin (Paris). 2005;63(2):145–54.PubMedGoogle Scholar
  41. 41.
    Carrière I, Fourrier-Reglat A, Dartigues J-F, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317–24.CrossRefGoogle Scholar
  42. 42.
    Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer’s disease. Biol Psychiatry. 2012;71(9):805–13.CrossRefGoogle Scholar
  43. 43.
    Hirota C, Watanabe M, Sun W, et al. Association between the Trail Making Test and physical performance in elderly Japanese. Geriatr Gerontol Int. 2010;10(1):40–7.CrossRefGoogle Scholar
  44. 44.
    Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;(9):CD007146.Google Scholar
  45. 45.
    Andre L, Gallini A, Montastruc F, et al. Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. Eur J Clin Pharmacol. 2019;75(12):1631–44.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.INSERM, UniCaen, U1075, COMETE, PFRSNormandie UniversityCaen CedexFrance
  2. 2.Department of GeriatricsCHU CaenCaenFrance
  3. 3.Department of Statistics and Clinical ResearchCHU CaenCaenFrance
  4. 4.Department of RheumatologyCHU CaenCaenFrance

Personalised recommendations